Open Questions: Neurodegeneration

Ranked research questions extracted from wiki pages and knowledge gaps
Field: GenesProteinsMechanismsTherapeuticsDiseasesPathwaysCell TypesBrain RegionsMethods
Sort by: Importance Elo Potential Impact Tractability
26 questions found for field 'Neurodegeneration'
open ⚖ 1500
Does selective overexpression of ALOX15 in reactive astrocytes preferentially increase anti-inflammatory LXA4 production, or does it simultaneously elevate pro-inflammatory 15-HETE under neuroinflamma
📑 0.50 💥 0.50
open ⚖ 1500
Is there a conserved 'natural resolution phase' in the circadian cycle that governs SPM biosynthesis efficiency, and does chronotherapeutic activation of maresin biosynthesis during early morning hour
📑 0.50 💥 0.50
open ⚖ 1500
Do protein aggregates in Alzheimer's and Parkinson's disease physically overwhelm microglial phagocytic clearance capacity regardless of receptor activation status, making GPR32 agonism insufficient a
📑 0.50 💥 0.50
open ⚖ 1500
How do the 32 reproducible gene expression signatures mechanistically contribute to neurodevelopmental and neurodegenerative disease etiology?
📑 0.50 💥 0.50
open ⚖ 1500
What molecular mechanisms trigger the transition from the early slow-accumulation phase to the later exponential-accumulation phase of Alzheimer pathology?
📑 0.50 💥 0.50
open ⚖ 1500
Does delta-catenin loss mechanistically contribute to Alzheimer's disease pathogenesis, and if so, what is the nature of its functional interaction with presenilin-1 (PS1) mutations in FAD?
📑 0.50 💥 0.50
open ⚖ 1500
Are the reductions in N-cadherin and PSD-95 the primary drivers of the cognitive and synaptic plasticity deficits observed in delta-cat(-/-) mice, or do they represent downstream epiphenomena?
📑 0.50 💥 0.50
open ⚖ 1500
What are the molecular and cellular mechanisms that confer individual variation in resilience to neurodegenerative pathology despite similar levels of AD pathology?
📑 0.50 💥 0.50
open ⚖ 1500
Does the identified relationship between dementia and RNA quality reflect a causal effect of RNA degradation on cognitive decline, or is poor RNA quality a consequence of existing neurodegenerative pa
📑 0.50 💥 0.50
open ⚖ 1500
What molecular or cellular features confer selective vulnerability of VENs to neurodegenerative and neuropsychiatric diseases despite their identity as regionally specialized ET neurons?
📑 0.50 💥 0.50
open ⚖ 1500
What is the functional significance of the 'strikingly specific regional signature' that distinguishes frontoinsula VENs from ET neurons in other cortical regions?
📑 0.50 💥 0.50
open ⚖ 1500
What molecular and cellular factors distinguish the subset of donors with severe cellular and molecular phenotypes who show steeper cognitive decline?
📑 0.50 💥 0.50
open ⚖ 1500
What are the underlying causal mechanisms driving the observed temporal sequence of different cellular perturbations across disease progression?
📑 0.50 💥 0.50
open ⚖ 1500
How do the cell type-specific gene expression changes mechanistically contribute to cognitive decline in AD?
📑 0.50 💥 0.50
open ⚖ 1500
What are the precise molecular mechanisms by which peripheral inflammation drives blood-brain barrier dysfunction in neurodegenerative diseases?
📑 0.50 💥 0.50
open ⚖ 1500
Does habitual motor performance directly accelerate dopaminergic neuron loss in the caudal sensorimotor striatum, or does it merely correlate with vulnerability?
📑 0.50 💥 0.50
open ⚖ 1500
What is the minimum threshold and duration of habitual behavioral reliance required to trigger neurodegeneration in at-risk individuals?
📑 0.50 💥 0.50
open ⚖ 1500
What are the causal biological mechanisms mediating the association between higher social status and younger transcriptional ages in female primates?
📑 0.50 💥 0.50
open ⚖ 1500
Do male rhesus macaques exhibit similar or different relationships between social status and brain transcriptional aging compared to females?
📑 0.50 💥 0.50
open ⚖ 1500
What are the functional consequences of age-related increases in gene expression variance for neural circuit stability and neurodegenerative disease susceptibility?
📑 0.50 💥 0.50
open ⚖ 1500
Whether these validated systems will be successfully adopted and integrated into routine clinical practice and clinical trials remains unclear.
📑 0.50 💥 0.50
open ⚖ 1500
Whether these systems perform consistently across diverse Parkinson's disease populations, including different disease stages and comorbidities, is unknown.
📑 0.50 💥 0.50
open ⚖ 1500
Whether the captured clinically relevant parameters reliably track disease progression or treatment response over time in unsupervised environments is not validated.
📑 0.50 💥 0.50
open ⚖ 1500
What specific cellular and molecular pathologies does SEA-AD identify as underlying Alzheimer's disease progression?
📑 0.50 💥 0.50
open ⚖ 1500
Are the cellular and molecular alterations identified specific to Alzheimer's disease or generalizable to related dementias?
📑 0.50 💥 0.50
open ⚖ 1500
How do the cellular Atlas findings correlate with longitudinal clinical outcomes and disease progression trajectories?
📑 0.50 💥 0.50
Open Questions | Part of the SciDEX Atlas layer | API | Cross-field map